ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 176 filers reported holding ASCENDIS PHARMA A/S in Q4 2020. The put-call ratio across all filers is 1.39 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $78,920 | +15.2% | 842,801 | +9.8% | 1.23% | +25.1% |
| Q2 2023 | $68,493 | -25.0% | 767,427 | -9.9% | 0.98% | -26.4% |
| Q1 2023 | $91,360 | -5.5% | 852,080 | +7.7% | 1.34% | -2.9% |
| Q4 2022 | $96,635 | -99.9% | 791,245 | +23.7% | 1.38% | +49.6% |
| Q3 2022 | $66,053,000 | +58.0% | 639,675 | +42.3% | 0.92% | +57.6% |
| Q2 2022 | $41,799,000 | -28.8% | 449,650 | -10.2% | 0.58% | -11.5% |
| Q1 2022 | $58,733,000 | -19.8% | 500,450 | -8.1% | 0.66% | +1.5% |
| Q4 2021 | $73,278,000 | -21.3% | 544,700 | -6.8% | 0.65% | -20.2% |
| Q3 2021 | $93,148,000 | +94.9% | 584,400 | +60.9% | 0.81% | +107.9% |
| Q2 2021 | $47,792,000 | -20.5% | 363,300 | -22.1% | 0.39% | -24.1% |
| Q1 2021 | $60,097,000 | -16.8% | 466,300 | +7.6% | 0.52% | -12.3% |
| Q4 2020 | $72,249,000 | +8.4% | 433,200 | +0.3% | 0.59% | -5.9% |
| Q3 2020 | $66,645,000 | +96.3% | 431,860 | +88.1% | 0.62% | +92.6% |
| Q2 2020 | $33,952,000 | – | 229,560 | – | 0.32% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 2,003,147 | $225,574,000 | 20.44% |
| RA Capital Management | 4,914,955 | $553,473,000 | 17.48% |
| Sofinnova Investments, Inc. | 1,109,874 | $124,983,000 | 11.56% |
| Eversept Partners, LP | 275,494 | $31,023,379 | 7.71% |
| Avoro Capital Advisors LLC | 1,787,000 | $201,234,000 | 6.79% |
| Orbimed Advisors | 3,287,400 | $370,194,000 | 6.22% |
| Eventide Asset Management | 1,698,648 | $191,285,000 | 6.19% |
| Logos Global Management LP | 120,000 | $13,513,000 | 5.14% |
| Ghost Tree Capital, LLC | 150,000 | $16,892,000 | 4.48% |
| Spyglass Capital Management LLC | 351,388 | $39,570,000 | 4.47% |